nature neuroscience

Corresponding Author:	Geoffrey Schoenbaum	# Main Figures:	5
Manuscript Number:	NN-A56755-A (RE-REVISION)	# Supplementary Figures:	4
Manuscript Type:	Article	# Supplementary Tables:	0
		# Supplementary Videos:	0

Reporting Checklist for Nature Neuroscience

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. For more information, please read Reporting Life Sciences Research.

Please note that in the event of publication, it is mandatory that authors include all relevant methodological and statistical information in the manuscript.

Statistics reporting, by figure

- Please specify the following information for each panel reporting quantitative data, and where each item is reported (section, e.g. Results, & paragraph number).
- Each figure legend should ideally contain an exact sample size (n) for each experimental group/condition, where n is an exact number and not a range, a clear definition of how n is defined (for example x cells from x slices from x animals from x litters, collected over x days), a description of the statistical test used, the results of the tests, any descriptive statistics and clearly defined error bars if applicable.
- For any experiments using custom statistics, please indicate the test used and stats obtained for each experiment.
- Each figure legend should include a statement of how many times the experiment shown was replicated in the lab; the details of sample collection should be sufficiently clear so that the replicability of the experiment is obvious to the reader.
- For experiments reported in the text but not in the figures, please use the paragraph number instead of the figure number.

Note: Mean and standard deviation are not appropriate on small samples, and plotting independent data points is usually more informative. When technical replicates are reported, error and significance measures reflect the experimental variability and not the variability of the biological process; it is misleading not to state this clearly.

		TEST USED		n			DESCRIPTIVE STATS (AVERAGE, VARIANCE)		P VALUE		DEGREES OF FREEDOM & F/t/z/R/ETC VALUE	
	FIGURE NUMBER	WHICH TEST?	SECTION & PARAGRAPH #	EXACT VALUE	DEFINED?	SECTION & PARAGRAPH #	REPORTED?	SECTION & PARAGRAPH #	EXACT VALUE	SECTION & PARAGRAPH #	VALUE	SECTION & PARAGRAPH #
example	1a	one-way ANOVA	Fig. legend	9, 9, 10, 15	mice from at least 3 litters/group	Methods para 8	error bars are mean +/- SEM	Fig. legend	p = 0.044	Fig. legend	F(3, 36) = 2.97	Fig. legend
example	results, para 6	unpaired t- test	Results para 6	15	slices from 10 mice	Results para 6	error bars are mean +/- SEM	Results para 6	p = 0.0006	Results para 6	t(28) = 2.808	Results para 6

		TEST US	ST USED		n		DESCRIPTIVE STATS (AVERAGE, VARIANCE)		P VALUE		DEGREES OF FREEDOM & F/t/z/R/ETC VALUE	
	FIGURE NUMBER	WHICH TEST?	SECTION & PARAGRAPH #	EXACT VALUE	DEFINED?	SECTION & PARAGRAPH #	REPORTED?	SECTION & PARAGRAPH #	EXACT VALUE	SECTION & PARAGRAPH #	VALUE	SECTION & PARAGRAPH #
+ -	2a	ANOVA	descrip tion of first experi ment	37	rats in two groups	start of descriptio n of first experime nt	data and SEM plotted in fig 2	fig 2a	multiple, please see text for relevant p's	results of first expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of first expt
+	2b	ANOVA and posthocs	descrip tion of first experi ment	37	rats in two groups	start of descriptio n of first experime nt	data and SEM plotted in fig 2	fig 2b	multiple, please see text for relevant p's	results of first expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of first expt
+	2c	ANOVA and posthocs	descrip tion of first experi ment	37	rats in two groups	start of descriptio n of first experime nt	data and SEM plotted in fig 2	fig 2c	multiple, please see text for relevant p's	results of first expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of first expt
+	fig 3	ANOVAs	descrip tion of first experi ment	10	rats in two groups	descriptio n of devaluati on experime nt	data and SEM plotted in fig 3	fig 3	multiple, please see text for relevant p's	results of first expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of first expt
+	5a	ANOVAs	descrip tion of second experi ment	41	rats in two groups	start of descriptio n of second experime nt	data and SEM plotted in fig 5	fig 5a	multiple, please see text for relevant p's	results of second expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of second expt
+	5b	ANOVAs	descrip tion of second experi ment	41	rats in two groups	start of descriptio n of second experime nt	data and SEM plotted in fig 5	fig 5b	multiple, please see text for relevant p's	results of second expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of second expt
+	5c	ANOVAs	descrip tion of second experi ment	41	rats in two groups	start of descriptio n of second experime nt	data and SEM plotted in fig 5	fig 5c	multiple, please see text for relevant p's	results of second expt	multiple, depending on effect/ interaction in multifactor factor anova, please see text	results of second expt

Representative figures

1. Are any representative images shown (including Western blots and immunohistochemistry/staining) in the paper?

If so, what figure(s)?

2. For each representative image, is there a clear statement of how many times this experiment was successfully repeated and a discussion of any limitations in repeatability?

If so, where is this reported (section, paragraph #)?

Yes fig 1 and 4

the figures show histology showing expression. the methods describe the number of rats and extent of expression is in the results.

Statistics and general methods

1. Is there a justification of the sample size?

If so, how was it justified?

Where (section, paragraph #)?

Even if no sample size calculation was performed, authors should report why the sample size is adequate to measure their effect size.

2. Are statistical tests justified as appropriate for every figure?

Where (section, paragraph #)?

- a. If there is a section summarizing the statistical methods in the methods, is the statistical test for each experiment clearly defined?
- b. Do the data meet the assumptions of the specific statistical test you chose (e.g. normality for a parametric test)?

Where is this described (section, paragraph #)?

c. Is there any estimate of variance within each group of data?

Is the variance similar between groups that are being statistically compared?

Where is this described (section, paragraph #)?

d. Are tests specified as one- or two-sided?

e. Are there adjustments for multiple comparisons?

sample sizes are based on past experience, and is justified with references to prior papers showing the effect we are replicating here.

yes. statistical tests are described throughout the results. typically we use ANOVA's with interactions between groups or main effects, with posthocs. In response to some of the new reviewer comments, we also use MANOVA as described in supplemental.

yes there are clear descriptions of the statistics for each experiment in the text

yes. the statistics are described and enumerated throughout the results.

we assume the variance is normal, but we have not formally tested it. we say this in the methods.

tests are two sided.

we do not do multiple comparisons. data from each phase are analyzed via ANOVA based on a priori predictions . only with appropriate main effects or interactions do we do posthocs.

- 4. Are criteria for excluding data points reported? Was this criterion established prior to data collection? Where is this described (section, paragraph #)?
- 5. Define the method of randomization used to assign subjects (or samples) to the experimental groups and to collect and process data.

If no randomization was used, state so.

Where does this appear (section, paragraph #)?

6. Is a statement of the extent to which investigator knew the group allocation during the experiment and in assessing outcome included?

If no blinding was done, state so.

Where (section, paragraph #)?

7. For experiments in live vertebrates, is a statement of compliance with yes in the first paragraph of the methods. ethical guidelines/regulations included?

Where (section, paragraph #)?

8. Is the species of the animals used reported?

Where (section, paragraph #)?

9. Is the strain of the animals (including background strains of KO/ transgenic animals used) reported?

Where (section, paragraph #)?

10. Is the sex of the animals/subjects used reported?

Where (section, paragraph #)?

11. Is the age of the animals/subjects reported?

Where (section, paragraph #)?

12. For animals housed in a vivarium, is the light/dark cycle reported?

Where (section, paragraph #)?

13. For animals housed in a vivarium, is the housing group (i.e. number of yes in the first paragraph of methods animals per cage) reported?

Where (section, paragraph #)?

we did not exclude any data points. several rats were excluded during the experiments for illness or virus/cannula misplacement. their data were not analyzed.

we did not randomize subjects. they were assigned to control or expt groups based on whether they received eYFP or ChR2 or NpHR infusions. all data collection was by computer. identity of cues was counterbalanced. all of this is described in our methods.

all data collection was by computer.

done

yes in the first paragraph of methods.

yes in the first paragraph of methods and in main text.

yes in the first paragraph of methods.

yes in the first paragraph of methods

yes in the first paragraph of methods

dark	cycl	e)?	
Whe	ere (s	ection, paragraph #)?	
45 1 1			
		evious history of the animals/subjects (e.g. prior drug ration, surgery, behavioral testing) reported?	no prior history
Whe	ere (s	ection, paragraph #)?	
	a.	If multiple behavioral tests were conducted in the same group of animals, is this reported?	yes this is described clearly in the entire paper. it is two experiments basically, each conducted on a new set of rats.
		Where (section, paragraph #)?	
16. If an	ny an	imals/subjects were excluded from analysis, is this reported?	we excluded 10 subjects who failed to show viral expression within VTA or whose fibers were not located within the VTA or who could
Whe	ere (s	ection, paragraph #)?	not enter the food cup with the fibers on their heads to respond. exclusions were made prior to data analysis, and thus they are not reported in the manuscript.
	a.	How were the criteria for exclusion defined?	criterion for inclusion were that fibers were located within the target area in VTA and that there was visible viral expression in VTA.
		Where is this described (section, paragraph #)?	
	b.	Specify reasons for any discrepancy between the number of animals at the beginning and end of the study.	none

yes in the first paragraph of methods

Where is this described (section, paragraph #)?

14. For behavioral experiments, is the time of day reported (e.g. light or

Reagents

- 1. Have antibodies been validated for use in the system under study (assay and species)?
 - a. Is antibody catalog number given?

Where does this appear (section, paragraph #)?

b. Where were the validation data reported (citation, supplementary information, Antibodypedia)?

Where does this appear (section, paragraph #)?

- 2. Cell line identity
 - Are any cell lines used in this paper listed in the database of commonly misidentified cell lines maintained by <u>ICLAC</u> and <u>NCBI Biosample</u>?

Where (section, paragraph #)?

no

- If yes, include in the Methods section a scientific justification of their use--indicate here in which section and paragraph the justification can be found.
- c. For each cell line, include in the Methods section a statement that specifies:
 - the source of the cell lines
 - have the cell lines been authenticated? If so, by which method?
 - have the cell lines been tested for mycoplasma

contamination?

Where (section, paragraph #)?

Data availability

Provide a Data availability statement in the Methods section under "Data availability", which should include, where applicable:
Accession codes for deposited data
Other unique identifiers (such as DOIs and hyperlinks for any other datasets)
At a minimum, a statement confirming that all relevant data are available from the authors

- Formal citations of datasets that are assigned DOIs
- A statement regarding data available in the manuscript as source data
- A statement regarding data available with restrictions
- See our data availability and data citations policy page for more information.

Data deposition in a public repository is mandatory for:

- a. Protein, DNA and RNA sequences
 - b. Macromolecular structures
 - c. Crystallographic data for small molecules
 - d. Microarray data
- Deposition is strongly recommended for many other datasets for which structured public repositories exist; more details on our data policy are available here. We encourage the provision of other source data in supplementary information or in unstructured repositories such as Figshare and Dryad.
- We encourage publication of Data Descriptors (see Scientific Data) to maximize data reuse.
- Where is the Data Availability statement provided (section, paragraph #)?

Data is available from the authors as per NIH policy.

Computer code/software

Any custom algorithm/software that is central to the methods must be supplied by the authors in a usable and readable form for readers at the time of publication. However, referees may ask for this information at any time during the review process.

- Identify all custom software or scripts that were required to conduct the study and where in the procedures each was used.
- If computer code was used to generate results that are central to the paper's conclusions, include a statement in the Methods section under "Code availability" to indicate whether and how the code can be accessed. Include version information as necessary and any restrictions on availability.

Computer programs were written and anlayses were run using commercially available software.

All information about the computer programs used is in the methods .

Human subjects

- Which IRB approved the protocol?
 Where is this stated (section, paragraph #)?
- Is demographic information on all subjects provided?
 Where (section, paragraph #)?
- Is the number of human subjects, their age and sex clearly defined?
 Where (section, paragraph #)?
- Are the inclusion and exclusion criteria (if any) clearly specified? Where (section, paragraph #)?
- 5. How well were the groups matched?

Where is this information described (section, paragraph #)?

6. Is a statement included confirming that informed consent was obtained from all subjects?

Where (section, paragraph #)?

7. For publication of patient photos, is a statement included confirming that consent to publish was obtained?

Where (section, paragraph #)?

fMRI studies

For papers reporting functional imaging (fMRI) results please ensure that these minimal reporting guidelines are met and that all this information is clearly provided in the methods:

- 1. Were any subjects scanned but then rejected for the analysis after the data was collected?
 - a. If yes, is the number rejected and reasons for rejection described?

Where (section, paragraph #)?

2. Is the number of blocks, trials or experimental units per session and/ or subjects specified?

Where (section, paragraph #)?

- 3. Is the length of each trial and interval between trials specified?
- Is a blocked, event-related, or mixed design being used? If applicable, please specify the block length or how the event-related or mixed design was optimized.
- 5. Is the task design clearly described?

Where (section, paragraph #)?

- 6. How was behavioral performance measured?
- 7. Is an ANOVA or factorial design being used?
- 8. For data acquisition, is a whole brain scan used?

If not, state area of acquisition.

- a. How was this region determined?
- 9. Is the field strength (in Tesla) of the MRI system stated?
 - a. Is the pulse sequence type (gradient/spin echo, EPI/spiral) stated?
 - b. Are the field-of-view, matrix size, slice thickness, and TE/TR/ flip angle clearly stated?
- 10. Are the software and specific parameters (model/functions, smoothing kernel size if applicable, etc.) used for data processing and pre-processing clearly stated?

- Is the coordinate space for the anatomical/functional imaging data clearly defined as subject/native space or standardized stereotaxic space, e.g., original Talairach, MNI305, ICBM152, etc? Where (section, paragraph #)?
- 12. If there was data normalization/standardization to a specific space template, are the type of transformation (linear vs. nonlinear) used and image types being transformed clearly described? Where (section, paragraph #)?
- 13. How were anatomical locations determined, e.g., via an automated labeling algorithm (AAL), standardized coordinate database (Talairach daemon), probabilistic atlases, etc.?
- 14. Were any additional regressors (behavioral covariates, motion etc) used?
- 15. Is the contrast construction clearly defined?
- 16. Is a mixed/random effects or fixed inference used?
 - a. If fixed effects inference used, is this justified?
- 17. Were repeated measures used (multiple measurements per subject)?
 - a. If so, are the method to account for within subject correlation and the assumptions made about variance clearly stated?
- 18. If the threshold used for inference and visualization in figures varies, is this clearly stated?
- 19. Are statistical inferences corrected for multiple comparisons?
 - a. If not, is this labeled as uncorrected?
- 20. Are the results based on an ROI (region of interest) analysis?
 - a. If so, is the rationale clearly described?
 - b. How were the ROI's defined (functional vs anatomical localization)?
- 21. Is there correction for multiple comparisons within each voxel?
- 22. For cluster-wise significance, is the cluster-defining threshold and the corrected significance level defined?

Additional comments

Additional Comments

